Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Horizon Discovery Group plc. (9/14/18). "Press Release: Horizon Discovery Edit-R crRNA Libraries Adopted by AstraZeneca as Part of Its Functional Genomics Discovery Platform". Cambridge.

Organisations Organisation Horizon Discovery Group plc (LSE: HZD)
  Group PerkinElmer (Group)
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product Edit-R™ crRNA libraries
  Product 2 functional genomics
Index term Index term AstraZeneca–Horizon Discovery: genomic libraries, 201809– supply adoption of Edit-R crRNA libraries for funcitonal genomics discovery platform by AZ
Persons Person Pizzie, Terry (Horizon Discovery 201702– before Pacific BiosciencesVP Europe before Genetix + Biacore + ABI)
  Person 2 Rees, Steve (AstraZeneca 201712 VP Discovery Biology)

> AstraZeneca joins Horizon’s Genomics Discovery Initiative

> CRISPR knockout and activation libraries are a key toolset in early research

> crRNA libraries are an efficient and convenient platform for gain- and loss-of-function studies

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces AstraZeneca has adopted its Edit-R™ crRNA libraries as part of AstraZeneca’s drive to establish a functional genomics discovery platform. AstraZeneca also joins the Genomics Discovery Initiative (GDI), a collaborative functional genomics screening community facilitated by Horizon.

AstraZeneca has been evaluating Horizon’s Edit-R human whole genome crRNA library for gene knockout since late 2017, and will soon add the Company’s platform of arrayed synthetic crRNA libraries for CRISPR-mediated transcriptional activation (CRISPRa). The libraries offer a powerful tool for functional genomic screens in drug discovery, providing deeper insight into biological mechanisms for the purpose of understanding disease progression, host-pathogen relationships, drug interactions, and pathway analysis.

Horizon’s Edit-R CRISPR-Cas9 synthetic crRNA libraries for both knockout (loss-of-function) and activation (gain-of-function) enable whole genome analysis in an arrayed format, allowing researchers to carry out high-content, multiparametric analyses on a one-well-per-gene basis. The portfolio includes catalog libraries for popular human and mouse gene families, in addition to druggable gene targets and the whole human genome. Bespoke collections are also available to support researchers working with a specialized gene target list.

Terry Pizzie, Chief Executive Officer, Horizon Discovery, commented: “Our ongoing relationship with AstraZeneca is providing valuable insights into the scope and capabilities of CRISPR screening, which will be of benefit to the research and discovery community, ultimately bringing drugs to market faster.”

Steve Rees, Head of Discovery Biology, IMED Biotech Unit at AstraZeneca, said: “The scientific support and degree of collaboration with the scientists at Horizon has been really impactful in ensuring we are able to harness the full potential of the platform. We have been impressed with the performance of the Edit-R synthetic crRNA, and look forward to feeding our drug discovery pipeline with data generated from the CRISPRa crRNA libraries.”

Horizon’s Genomics Discovery Initiative ( brings together visionary research institutions and investigators, to serve as a network for education, trends, advancements, and sharing of best-practices. The Initiative has over 60 member institutes worldwide, has generated multiple shared publications, and hundreds of published whole genome siRNA screens.

For more information about Horizon’s CRISPRa reagents and screening services please visit: and


For further information from Horizon Discovery Group plc, please contact:

Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947

Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580

About Horizon Discovery Group plc

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon’s platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalized molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company’s own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD.”

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit and follow us on Twitter @AstraZeneca.

Record changed: 2018-09-20


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for PerkinElmer (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top